Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Mar;27(2):199-210.
doi: 10.1111/hae.14233. Epub 2021 Feb 6.

Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: A systematic literature review

Natacha Dewarrat  1 , Mathilde Gavillet  1 , Anne Angelillo-Scherrer  2 , Olaia Naveiras  1 , Francesco Grandoni  1 , Dimitrios A Tsakiris  3 , Lorenzo Alberio  1 , Sabine Blum  1
Affiliations
Case Reports

Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: A systematic literature review

Natacha Dewarrat et al. Haemophilia. 2021 Mar.

Abstract

Background: About 1%-5% of acquired haemophilia A cases affect mothers in the postpartum setting.

Aims: This study delineates the characteristics of this disease, specific to the postpartum setting, notably relapse in subsequent pregnancies.

Methods: Report of two cases and literature study (1946-2019), yielding 73 articles describing 174 cases (total 176 cases).

Results: Patients were aged 29.9 years (17-41) and 69% primigravidae. Diagnosis was made at a median of 60 days after delivery (range 0-308). Bleeding types were obstetrical (43.4%), cutaneous (41.3%), and muscular (36.7%). In >90% of the cases, FVIII at diagnosis was <1% (range 0%-8%). FVIII inhibitor was documented in 75.4% cases (median titre of 20 BU/ml, range 1-621). Haemostatic treatment was necessary in 57.1% using fresh frozen plasma (16%), factor concentrate (27.6%) and/or bypassing agents (37.4%). Immunosuppressive treatment was administered in 90.8%, mostly steroids (85.3%), alone or combined with immunosuppressants (27%). Rituximab was used mostly as a second line treatment. Only 24 patients (13.6%) had documented subsequent pregnancies and 6 (22.2%) suffered haemophilia recurrence during pregnancy.

Conclusion: This study allows better definition of: (1) clinical and laboratory characteristics of postpartum acquired haemophilia, (2) response to therapy, and (3) the risk of relapse for subsequent pregnancies.

Keywords: Factor VIII deficiency; Haemophilia A; acquired; postpartum haemorrhage; postpartum period; recurrence.

PubMed Disclaimer

References

REFERENCES

    1. Sborov DW, Rodgers GM. How I manage patients with acquired haemophilia A. Br J Haematol. 2013;161:157-165.
    1. Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007;109:1870-1877.
    1. Piccinni M-P, Lombardelli L, Logiodice F, Kullolli O, Parronchi P, Romagnani S. How pregnancy can affect autoimmune diseases progression? Clin Mol Allergy. 2016;14:11.
    1. Lateef A, Petri M. Managing lupus patients during pregnancy. Best Pract Res Clin Rheumatol. 2013;27:435-447.
    1. Tiede A, Eisert R, Czwalinna A, Miesbach W, Scharrer I, Ganser A. Acquired haemophilia caused by non-haemophilic factor VIII gene variants. Ann Hematol. 2010;89:607-612.

LinkOut - more resources